Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: A pilot study

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 7, 2004, Pages 400-404

  Wenzel, Catharina ^a   Hussian, Dagmar ^a   Bartsch, Rupert ^a   Pluschnig, Ursula ^a   Locker, Gottfried J ^a   Rudas, Margarethe ^a   Gnant, Michael F ^a   Jakesz, Raimund ^a   Zielinski, Christoph C ^a,b   Steger, Guenther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; Docetaxel; Epidoxorubicin; Neoadjuvant; Trastuzumab

Indexed keywords

DOCETAXEL; EPIRUBICIN; TRASTUZUMAB;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; FEMALE; FEVER; HUMAN; INFECTION; LEUKOPENIA; LUNG TOXICITY; MAINTENANCE DRUG DOSE; NAIL DISEASE; NAUSEA; OUTPATIENT; PILOT STUDY; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA;

EID: 3843106892     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0559-6     Document Type: Article

References (24)

1. Bellot R, Robert J, Dieras V, Misset JL, Baille P, Bozec L, Vernillet L, Riva A, Azli N, Pouillart P (1998) Taxotere does not change the pharmacokinetic profile of doxorubicin and doxorubicinol. Proc Am Soc Clin Oncol 17:221a (Abstract 853)
2. Burstein HJ, Manola J, Younger J, Parker LM, Bunell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212-1219
3. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21:46-53
4. Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL, Lentz MA, Azli N, Murawsky M, Riva A, Pouillart P, Fumoleau P (1996) A multicentre phase II study of docetaxel 75 mg/m2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer 74:650-656
5. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493
6. Gennari A, Salvadori B, Donati S, Bengala C, Orlandini C, Danesi R, Del Tacca M, Bruzzi P, Conte PF (1999) Cardiotoxicity of epirubicin/paclitaxel- containing regimens: Role of cardiac risk factors. J Clin Oncol 17:3596-3602
7. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics 2003. J Clin Oncol 53:5-26
8. Luporsi E, Vanlemmens L, Coudert B, Mayer F, Bonneterre J, Petit T, Borel C, Hirsch M, Bey P (2000) 6 cycles of FEC 100 vs 6 cycles of epirubicin-docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients (Pts): Preliminary results of a randomized phase II trial of GIREC SO1. Proc Am Soc Clin Oncol 19:92a (Abstract 355)
9. Mencel PJ, Lerner WA, Topilow AA, Greenberg SN, Pomponi DA, Virdi JK, Kuo Y (2000) Adjuvant chemotherapy of sequential docetaxel (D) and adriamycin (A) in patients with stage II and III completely resected breast cancer. Proc Am Soc Clin Oncol, 19:143a (Abstract 563)
10. Milla-Santos A, Anton-Aparicio A, Gonzalez-Baron M, Milla I, Solano V, Rallo I (2000) Docetaxel (D) plus high dose epirubicin (E) with lenograstim (L) support as first line therapy in advanced breast cancer (ABC). A phase II study. Proc Am Soc Clin Oncol 19:107a (Abstract 413)
11. Nabholtz JM, Riva A (2001) Taxane/anthracycline combinations: setting a new standard in breast cancer? Oncologist 6:5-12
12. Norton L, Slamon D, Leyland-Jones B, Wolter J, Fleming T, Eirmann W, Baselga J, Mendelsohn J, Bajamonde A, Ash M, Shak S (1999) Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 18:127a (Abstract 483)
13. Pazos C, Mickiewicz E, Di Notto MR, Coppola F, Ventriglia M, Jovtis S, Balbiani L, Lewi D, Rondinon M, Temperley G, Trigo M, Bertoncin AM, Pascual M, Uranga G, Cazap E, Breier S, Grasso S, Estevez R, Triguboff E, Alvarez A, Suarez A (1999) Phase II of doxorubicin/taxol in metastatic breast cancer. A Multicenter Taxol Group. Breast Cancer Res Treat 55:91-96
14. Piccart MJ, Biganzoli L, Di Leo A (2000) The impact of chemotherapy dose density and dose intensity on breast cancer outcome: What have we learned? Eur J Cancer 36: S4-10
15. Reichman BS, Seidman AD, Crown JPA, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA, Yao TJ, Klecker R, Jamis-Dow C, Collins J, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuck S, Norton L (1993) Paclitaxel and recombinant human granulocyte-colony stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951
16. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangie T, Jouve M, Beuzeboc A, Garcio-Giralt E, Salmon RJ, De La Rochefordiere A, Campana F, Pouillart P (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast-conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645-652
17. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361
18. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenptype and gene amplification. J Clin Oncol 19:2587-2595
19. Slamon D, Leyland-Jones B, Shak S, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J, Norton L (1998) Addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc A Soc Clin Oncol, 17:98a (Abstract 377)
20. Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC (2000) Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol 18:2369-2377
21. Steger GG, Wenzel C, Schmidinger M, Locker GJ, Rudas M, Taucher S, Gnant M, Jakesz R (2000) HER2 status predicts complete pathological response (pCR) in primary, operable breast cancer (BC) treated with neoadjuvant epirubicin/docetaxel + G-CSF. Breast Cancer Res Treat 64:31 (Abstract 23)
22. Wenzel C, Schmidinger M, Locker GJ, Taucher S, Gnant M, Jakesz R, Steger GG (1999) Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T 1-4, N0-2, M0). Wien Klin Wochenschr 111:843-850
23. Wenzel C, Locker GJ, Pluschnig U, Zielinski CC, Rudas M, Oberhuber G, Gnant MF, Taucher S, Jakesz R, Steger GG (2002a) Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. Cancer Chemother Pharmacol 50:155-159
24. Wenzel C, Locker GJ, Schmidinger M, Rudas M, Taucher S, Gnant MF, Jakesz R, Steger GG (2002b) Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel + granulocyte colony stimulating factor. Anticancer Drugs 13:67-74